{"id":2028,"date":"2019-11-11T12:39:46","date_gmt":"2019-11-11T12:39:46","guid":{"rendered":"https:\/\/xspraypharma.com\/investerare\/bolagsstyrning\/ledning-copy\/"},"modified":"2026-05-08T08:27:15","modified_gmt":"2026-05-08T08:27:15","slug":"om-oss-ledning","status":"publish","type":"page","link":"https:\/\/xspraypharma.com\/sv\/om-oss\/om-oss-ledning\/","title":{"rendered":"Om oss – Ledningsgrupp"},"content":{"rendered":"\n
\n\t
\n\t\t\t\t\t
\n\t\t\t\t

Ledningsgrupp<\/h1>\n\t\t\t<\/header>\n\t\t\n\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t
\n\t
\n\t\t\t\t\t\"\"\t\t\t<\/figure>\n\n\t
\n\n\t\t

Blake Leitch<\/h3>\n\n\t\t\t\t\t

\n\t\t\t\tVerkst\u00e4llande Direkt\u00f6r\t\t\t<\/p>\n\t\t\n\t\t\t\t\t

\n\t\t\t\tVerkst\u00e4llande Direkt\u00f6r p\u00e5 Xspray Pharma sedan 2026.
\r\nF\u00f6dd 1975
\r\n
\r\nBlake Leitch har framg\u00e5ngsrikt arbetat med att lansera nya produkter, genomf\u00f6ra kommersiella strategier och driva expansion av verksamheter inom l\u00e4kemedelsindustrin i USA, Europa och Asien. Han kommer senast fr\u00e5n rollen som Vice President och kommersiellt ansvarig f\u00f6r den europeiska marknaden och medlem av det exekutiva ledningsteamet i Biocon Biologics. Han har tidigare haft liknande roller i de globala l\u00e4kemedelsbolagen Biogen och Bayer. Hans erfarenhet omfattar f\u00f6rs\u00e4ljning och utveckling av receptbelagda l\u00e4kemedel, biosimilarer, generiska l\u00e4kemedel och OTC-produkter.\t\t\t<\/p>\n\t\t\n\t\t\t\t\t

\n\t\t\t\tUtbildning:<\/strong>\n\t\t\t\tLakehead University och Harvard Business School\t\t\t<\/p>\n\t\t\n\t\t\t\t\t

\n\t\t\t\tUppdrag:<\/strong>\n\t\t\t\t–
\r\n
\r\nInnehav i bolaget: –
\r\n
\r\nOberoende i f\u00f6rh\u00e5llande till st\u00f6rre aktie\u00e4gare men inte till Bolaget.
\r\n
\r\n\t\t\t<\/p>\n\t\t\n\t\t\t\t\n\t<\/div>\n<\/article>\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t

\n\t
\n\t\t\t\t\t\"\"\t\t\t<\/figure>\n\n\t
\n\n\t\t

Per Andersson<\/h3>\n\n\t\t\t\t\t

\n\t\t\t\tChief Scientific Officer \t\t\t<\/p>\n\t\t\n\t\t\t\t\t

\n\t\t\t\tChief Scientific Officer sedan 2025
\r\nTidigare Verkst\u00e4llande Direkt\u00f6r p\u00e5 Xspray Pharma 2006-2026
\r\nF\u00f6dd 1967
\r\n
\r\nPer har en bakgrund som Science Director p\u00e5 Gyros Protein Therapeutics AB, d\u00e4r han utvecklade en helt ny banbrytande teknologi till n\u00e5got som nu \u00e4r l\u00f6nsamma produkter. Han har \u00f6ver 200 patent som uppfinnare och lyckosamt arbetat med patentstrategi i mer \u00e4n 25 \u00e5r. Tidigare arbetade han som senior forskare p\u00e5 Cytiva AB, d\u00e4r han fokuserade p\u00e5 teknologisk innovation. Per \u00e4r medf\u00f6rfattare p\u00e5 \u00f6ver 30 vetenskapliga publikationer.
\r\n
\r\n\t\t\t<\/p>\n\t\t\n\t\t\t\t\t

\n\t\t\t\tUtbildning:<\/strong>\n\t\t\t\tDoktorsexamen i analytisk kemi, Stockholms Universitet\t\t\t<\/p>\n\t\t\n\t\t\t\t\t

\n\t\t\t\tUppdrag:<\/strong>\n\t\t\t\tVerkst\u00e4llande direkt\u00f6r i Xspray Pharma Inc., styrelseordf\u00f6rande i Xspray Pharma Futurum AB och Robotic Lawn Care Sweden AB samt styrelsesuppleant i Journeyman Stockhom AB.
\r\n
\r\nInnehav i bolaget: 199 560 aktier och 310 923 optioner varav 103 641 teckningsoptioner och 207 282 personaloptioner.
\r\n
\r\nOberoende i f\u00f6rh\u00e5llande till st\u00f6rre aktie\u00e4gare men inte till Bolaget. \t\t\t<\/p>\n\t\t\n\t\t\t\t\t

\n\t\t\t\t\n\t\t\t\t\t<\/i>\n\t\t\t\t\tper.andersson@xspray.com\t\t\t\t<\/a>\n\t\t\t<\/p>\n\t\t\t\t\n\t<\/div>\n<\/article>\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t

\n\t
\n\t\t\t\t\t\"\"\t\t\t<\/figure>\n\n\t
\n\n\t\t

Niklas Adenborg<\/h3>\n\n\t\t\t\t\t

\n\t\t\t\tChief Financial Officer sedan 2024\t\t\t<\/p>\n\t\t\n\t\t\t\t\t

\n\t\t\t\tF\u00f6dd 1992
\r\n
\r\nNiklas har en bred erfarenhet inom finans och revision och har tidigare varit revisor p\u00e5 KPMG. Niklas ansl\u00f6t sig till Xspray Pharma 2019 och innehaft roller som Financial Controller och Finance Director.\t\t\t<\/p>\n\t\t\n\t\t\t\t\t

\n\t\t\t\tUtbildning:<\/strong>\n\t\t\t\tBachelor of Science in Business and Economics, Uppsala Universitet\t\t\t<\/p>\n\t\t\n\t\t\t\t\t

\n\t\t\t\tUppdrag:<\/strong>\n\t\t\t\tStyrelseordf\u00f6rande i P\u00e4ron AB, styrelseledamot i Brf Fl\u00f6jtbl\u00e5saren 7
\r\n
\r\nInnehav i bolaget: 1 721 aktier och 50 250 optioner varav 16 750 teckningsoptioner och 33 500 personaloptioner
\r\n
\r\nOberoende i f\u00f6rh\u00e5llande till st\u00f6rre aktie\u00e4gare men inte till Bolaget.
\r\n\t\t\t<\/p>\n\t\t\n\t\t\t\t\t

\n\t\t\t\t\n\t\t\t\t\t<\/i>\n\t\t\t\t\tniklas.adenborg@xspray.com\t\t\t\t<\/a>\n\t\t\t<\/p>\n\t\t\t\t\n\t<\/div>\n<\/article>\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t

\n\t
\n\t\t\t\t\t\"\"\t\t\t<\/figure>\n\n\t
\n\n\t\t

Mikael von Euler<\/h3>\n\n\t\t\t\t\t

\n\t\t\t\tChief Medical Officer sedan 2023\t\t\t<\/p>\n\t\t\n\t\t\t\t\t

\n\t\t\t\tF\u00f6dd 1953
\r\n
\r\nMikael \u00e4r onkolog med mer \u00e4n 35 \u00e5rs erfarenhet av l\u00e4kemedelsutveckling inom l\u00e4kemedelsindustrin. Han har innehaft flera seniora globala ledarroller vid stora l\u00e4kemedelsbolag, bland annat som Cluster Head f\u00f6r HER2 portf\u00f6ljen (Herceptin, pertuzumab, T DM1) p\u00e5 Roche\/Genentech, Vice President Oncology Europe p\u00e5 GlaxoSmithKline samt Global Product Director f\u00f6r Arimidex\/Nolvadex p\u00e5 AstraZeneca. Under de senaste 15 \u00e5ren har Mikael st\u00f6ttat mindre och nystartade bolag i ledande funktioner, som styrelseledamot och som oberoende konsult.\t\t\t<\/p>\n\t\t\n\t\t\t\t\t

\n\t\t\t\tUtbildning:<\/strong>\n\t\t\t\tMikael erh\u00f6ll sin l\u00e4karexamen (MD) och doktorsexamen (PhD) fr\u00e5n Karolinska Institutet i Stockholm, Sverige. Han \u00e4r Fellow of the Faculty of Pharmaceutical Medicine vid Royal Colleges of Physicians i Storbritannien.\t\t\t<\/p>\n\t\t\n\t\t\t\t\t

\n\t\t\t\tUppdrag:<\/strong>\n\t\t\t\t\u00c4gare och CEO i M von Euler Consulting AB, styrelseledamot i Dicot Pharma AB, Annexin Pharmaceuticals AB och Spago Nanomedical AB
\r\n
\r\nInnehav i bolaget: 3 730 aktier
\r\n
\r\nOberoende i f\u00f6rh\u00e5llande till st\u00f6rre aktie\u00e4gare men inte till Bolaget.\t\t\t<\/p>\n\t\t\n\t\t\t\t\n\t<\/div>\n<\/article>\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t

\n\t
\n\t\t\t\t\t\"\"\t\t\t<\/figure>\n\n\t
\n\n\t\t

Linda Glimberg<\/h3>\n\n\t\t\t\t\t

\n\t\t\t\tChief Operating Officer\t\t\t<\/p>\n\t\t\n\t\t\t\t\t

\n\t\t\t\tSenior Vice President Legal p\u00e5 Xspray Pharma sedan 2024
\r\nF\u00f6dd 1974
\r\n
\r\nLinda har arbetat mer \u00e4n 25 \u00e5r som jurist varav mer \u00e4n 15 \u00e5r som bolagsjurist i internationella bolag. Sedan 2018 driver hon egen konsultfirma och specialiserar sig p\u00e5 aff\u00e4rsjuridisk r\u00e5dgivning, fr\u00e4mst till l\u00e4kemedelsbolag. Hon har haft olika ledande positioner p\u00e5 bland annat AstraZeneca, Husqvarna och Keolis. \t\t\t<\/p>\n\t\t\n\t\t\t\t\t

\n\t\t\t\tUtbildning:<\/strong>\n\t\t\t\tJuristexamen, Uppsala universitet. Master of Laws (LLM) Cambridge University, England \t\t\t<\/p>\n\t\t\n\t\t\t\t\t

\n\t\t\t\tUppdrag:<\/strong>\n\t\t\t\t\u00c4gare och Styrelseledamot i Glimberg Holding AB och Glimberg Consulting AB, styrelseledamot i Robotic Lawn Care Sweden AB.
\r\n
\r\nInnehav i bolaget: 2 470 aktier via bolag och 10 026 optioner varav 3 342 teckningsoptioner och 6 684 personaloptioner.
\r\n
\r\nOberoende i f\u00f6rh\u00e5llande till st\u00f6rre aktie\u00e4gare men inte till Bolaget.
\r\n\t\t\t<\/p>\n\t\t\n\t\t\t\t\t

\n\t\t\t\t\n\t\t\t\t\t<\/i>\n\t\t\t\t\tlinda.glimberg@xspray.com\t\t\t\t<\/a>\n\t\t\t<\/p>\n\t\t\t\t\n\t<\/div>\n<\/article>\t\t\t\t\t\t\t\t\t\t\n\t\t\t\t<\/section>\n\n\t\t\t\t\t\t\n\t\t\t\t\n\t<\/div>\n<\/section>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":1,"featured_media":0,"parent":1707,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-2028","page","type-page","status-publish","hentry"],"acf":[],"yoast_head":"\nOm oss - Ledningsgrupp - Xspray<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/xspraypharma.com\/sv\/om-oss\/om-oss-ledning\/\" \/>\n<meta property=\"og:locale\" content=\"sv_SE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Om oss - Ledningsgrupp - Xspray\" \/>\n<meta property=\"og:url\" content=\"https:\/\/xspraypharma.com\/sv\/om-oss\/om-oss-ledning\/\" \/>\n<meta property=\"og:site_name\" content=\"Xspray\" \/>\n<meta property=\"article:modified_time\" content=\"2026-05-08T08:27:15+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/xspraypharma.com\/sv\/om-oss\/om-oss-ledning\/\",\"url\":\"https:\/\/xspraypharma.com\/sv\/om-oss\/om-oss-ledning\/\",\"name\":\"Om oss - Ledningsgrupp - Xspray\",\"isPartOf\":{\"@id\":\"https:\/\/xspraypharma.com\/sv\/#website\"},\"datePublished\":\"2019-11-11T12:39:46+00:00\",\"dateModified\":\"2026-05-08T08:27:15+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/xspraypharma.com\/sv\/om-oss\/om-oss-ledning\/#breadcrumb\"},\"inLanguage\":\"sv-SE\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/xspraypharma.com\/sv\/om-oss\/om-oss-ledning\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/xspraypharma.com\/sv\/om-oss\/om-oss-ledning\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/xspraypharma.com\/sv\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Om oss\",\"item\":\"https:\/\/xspraypharma.com\/sv\/om-oss\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Om oss – Ledningsgrupp\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/xspraypharma.com\/sv\/#website\",\"url\":\"https:\/\/xspraypharma.com\/sv\/\",\"name\":\"Xspray\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/xspraypharma.com\/sv\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"sv-SE\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Om oss - Ledningsgrupp - Xspray","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/xspraypharma.com\/sv\/om-oss\/om-oss-ledning\/","og_locale":"sv_SE","og_type":"article","og_title":"Om oss - Ledningsgrupp - Xspray","og_url":"https:\/\/xspraypharma.com\/sv\/om-oss\/om-oss-ledning\/","og_site_name":"Xspray","article_modified_time":"2026-05-08T08:27:15+00:00","twitter_card":"summary_large_image","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/xspraypharma.com\/sv\/om-oss\/om-oss-ledning\/","url":"https:\/\/xspraypharma.com\/sv\/om-oss\/om-oss-ledning\/","name":"Om oss - Ledningsgrupp - Xspray","isPartOf":{"@id":"https:\/\/xspraypharma.com\/sv\/#website"},"datePublished":"2019-11-11T12:39:46+00:00","dateModified":"2026-05-08T08:27:15+00:00","breadcrumb":{"@id":"https:\/\/xspraypharma.com\/sv\/om-oss\/om-oss-ledning\/#breadcrumb"},"inLanguage":"sv-SE","potentialAction":[{"@type":"ReadAction","target":["https:\/\/xspraypharma.com\/sv\/om-oss\/om-oss-ledning\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/xspraypharma.com\/sv\/om-oss\/om-oss-ledning\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/xspraypharma.com\/sv\/"},{"@type":"ListItem","position":2,"name":"Om oss","item":"https:\/\/xspraypharma.com\/sv\/om-oss\/"},{"@type":"ListItem","position":3,"name":"Om oss – Ledningsgrupp"}]},{"@type":"WebSite","@id":"https:\/\/xspraypharma.com\/sv\/#website","url":"https:\/\/xspraypharma.com\/sv\/","name":"Xspray","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/xspraypharma.com\/sv\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"sv-SE"}]}},"_links":{"self":[{"href":"https:\/\/xspraypharma.com\/sv\/wp-json\/wp\/v2\/pages\/2028","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/xspraypharma.com\/sv\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/xspraypharma.com\/sv\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/xspraypharma.com\/sv\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/xspraypharma.com\/sv\/wp-json\/wp\/v2\/comments?post=2028"}],"version-history":[{"count":24,"href":"https:\/\/xspraypharma.com\/sv\/wp-json\/wp\/v2\/pages\/2028\/revisions"}],"predecessor-version":[{"id":11386,"href":"https:\/\/xspraypharma.com\/sv\/wp-json\/wp\/v2\/pages\/2028\/revisions\/11386"}],"up":[{"embeddable":true,"href":"https:\/\/xspraypharma.com\/sv\/wp-json\/wp\/v2\/pages\/1707"}],"wp:attachment":[{"href":"https:\/\/xspraypharma.com\/sv\/wp-json\/wp\/v2\/media?parent=2028"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}